 | • レポートコード：MRC2-11QY03862 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は多発梗塞性認知症のグローバル市場について調査・分析したレポートです。種類別（薬理学的治療、非薬理学的治療）市場規模、用途別（学術用、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別多発梗塞性認知症の競争状況、市場シェア ・世界の多発梗塞性認知症市場：種類別市場規模 2015年-2020年（薬理学的治療、非薬理学的治療） ・世界の多発梗塞性認知症市場：種類別市場規模予測 2021年-2026年（薬理学的治療、非薬理学的治療） ・世界の多発梗塞性認知症市場：用途別市場規模 2015年-2020年（学術用、病院、その他） ・世界の多発梗塞性認知症市場：用途別市場規模予測 2021年-2026年（学術用、病院、その他） ・北米の多発梗塞性認知症市場分析：米国、カナダ ・ヨーロッパの多発梗塞性認知症市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの多発梗塞性認知症市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の多発梗塞性認知症市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの多発梗塞性認知症市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Forest Laboratories、Janssen Pharmaceuticals、Novartis Pharmaceutical、Pfizer、Eisai、Ortho-McNeil Pharmaceutical、Takeda、Jubilant Cadista Pharmaceuticals、Takeda Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Multi-cerebral infarction dementia is a series of small strokes that cause disruption of blood flow to the brain. It is the highest incidence among people over 65 years of age.
The increase in the global elderly population has also contributed to the development of the global market for multi-infarct dementia.
Market Analysis and Insights: Global Multi-Infarct Dementia Market
The global Multi-Infarct Dementia market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Multi-Infarct Dementia Scope and Market Size
Multi-Infarct Dementia market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Multi-Infarct Dementia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Forest Laboratories
Janssen Pharmaceuticals
Novartis Pharmaceutical
Pfizer
Eisai
Ortho-McNeil Pharmaceutical
Takeda
Jubilant Cadista Pharmaceuticals
Takeda Pharmaceutical
Market segment by Type, the product can be split into
Pharmacological Treatment
Non Pharmacological Treatment
Market segment by Application, split into
Academic
Hospitals
Other
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Multi-Infarct Dementia Revenue
1.4 Market by Type
1.4.1 Global Multi-Infarct Dementia Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Pharmacological Treatment
1.4.3 Non Pharmacological Treatment
1.5 Market by Application
1.5.1 Global Multi-Infarct Dementia Market Share by Application: 2020 VS 2026
1.5.2 Academic
1.5.3 Hospitals
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Multi-Infarct Dementia Market Perspective (2015-2026)
2.2 Global Multi-Infarct Dementia Growth Trends by Regions
2.2.1 Multi-Infarct Dementia Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Multi-Infarct Dementia Historic Market Share by Regions (2015-2020)
2.2.3 Multi-Infarct Dementia Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Multi-Infarct Dementia Market Growth Strategy
2.3.6 Primary Interviews with Key Multi-Infarct Dementia Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Multi-Infarct Dementia Players by Market Size
3.1.1 Global Top Multi-Infarct Dementia Players by Revenue (2015-2020)
3.1.2 Global Multi-Infarct Dementia Revenue Market Share by Players (2015-2020)
3.1.3 Global Multi-Infarct Dementia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Multi-Infarct Dementia Market Concentration Ratio
3.2.1 Global Multi-Infarct Dementia Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Multi-Infarct Dementia Revenue in 2019
3.3 Multi-Infarct Dementia Key Players Head office and Area Served
3.4 Key Players Multi-Infarct Dementia Product Solution and Service
3.5 Date of Enter into Multi-Infarct Dementia Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Multi-Infarct Dementia Historic Market Size by Type (2015-2020)
4.2 Global Multi-Infarct Dementia Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Multi-Infarct Dementia Market Size by Application (2015-2020)
5.2 Global Multi-Infarct Dementia Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Multi-Infarct Dementia Market Size (2015-2020)
6.2 Multi-Infarct Dementia Key Players in North America (2019-2020)
6.3 North America Multi-Infarct Dementia Market Size by Type (2015-2020)
6.4 North America Multi-Infarct Dementia Market Size by Application (2015-2020)
7 Europe
7.1 Europe Multi-Infarct Dementia Market Size (2015-2020)
7.2 Multi-Infarct Dementia Key Players in Europe (2019-2020)
7.3 Europe Multi-Infarct Dementia Market Size by Type (2015-2020)
7.4 Europe Multi-Infarct Dementia Market Size by Application (2015-2020)
8 China
8.1 China Multi-Infarct Dementia Market Size (2015-2020)
8.2 Multi-Infarct Dementia Key Players in China (2019-2020)
8.3 China Multi-Infarct Dementia Market Size by Type (2015-2020)
8.4 China Multi-Infarct Dementia Market Size by Application (2015-2020)
9 Japan
9.1 Japan Multi-Infarct Dementia Market Size (2015-2020)
9.2 Multi-Infarct Dementia Key Players in Japan (2019-2020)
9.3 Japan Multi-Infarct Dementia Market Size by Type (2015-2020)
9.4 Japan Multi-Infarct Dementia Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Multi-Infarct Dementia Market Size (2015-2020)
10.2 Multi-Infarct Dementia Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Multi-Infarct Dementia Market Size by Type (2015-2020)
10.4 Southeast Asia Multi-Infarct Dementia Market Size by Application (2015-2020)
11 India
11.1 India Multi-Infarct Dementia Market Size (2015-2020)
11.2 Multi-Infarct Dementia Key Players in India (2019-2020)
11.3 India Multi-Infarct Dementia Market Size by Type (2015-2020)
11.4 India Multi-Infarct Dementia Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Multi-Infarct Dementia Market Size (2015-2020)
12.2 Multi-Infarct Dementia Key Players in Central & South America (2019-2020)
12.3 Central & South America Multi-Infarct Dementia Market Size by Type (2015-2020)
12.4 Central & South America Multi-Infarct Dementia Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Forest Laboratories
13.1.1 Forest Laboratories Company Details
13.1.2 Forest Laboratories Business Overview
13.1.3 Forest Laboratories Multi-Infarct Dementia Introduction
13.1.4 Forest Laboratories Revenue in Multi-Infarct Dementia Business (2015-2020))
13.1.5 Forest Laboratories Recent Development
13.2 Janssen Pharmaceuticals
13.2.1 Janssen Pharmaceuticals Company Details
13.2.2 Janssen Pharmaceuticals Business Overview
13.2.3 Janssen Pharmaceuticals Multi-Infarct Dementia Introduction
13.2.4 Janssen Pharmaceuticals Revenue in Multi-Infarct Dementia Business (2015-2020)
13.2.5 Janssen Pharmaceuticals Recent Development
13.3 Novartis Pharmaceutical
13.3.1 Novartis Pharmaceutical Company Details
13.3.2 Novartis Pharmaceutical Business Overview
13.3.3 Novartis Pharmaceutical Multi-Infarct Dementia Introduction
13.3.4 Novartis Pharmaceutical Revenue in Multi-Infarct Dementia Business (2015-2020)
13.3.5 Novartis Pharmaceutical Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Multi-Infarct Dementia Introduction
13.4.4 Pfizer Revenue in Multi-Infarct Dementia Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Eisai
13.5.1 Eisai Company Details
13.5.2 Eisai Business Overview
13.5.3 Eisai Multi-Infarct Dementia Introduction
13.5.4 Eisai Revenue in Multi-Infarct Dementia Business (2015-2020)
13.5.5 Eisai Recent Development
13.6 Ortho-McNeil Pharmaceutical
13.6.1 Ortho-McNeil Pharmaceutical Company Details
13.6.2 Ortho-McNeil Pharmaceutical Business Overview
13.6.3 Ortho-McNeil Pharmaceutical Multi-Infarct Dementia Introduction
13.6.4 Ortho-McNeil Pharmaceutical Revenue in Multi-Infarct Dementia Business (2015-2020)
13.6.5 Ortho-McNeil Pharmaceutical Recent Development
13.7 Takeda
13.7.1 Takeda Company Details
13.7.2 Takeda Business Overview
13.7.3 Takeda Multi-Infarct Dementia Introduction
13.7.4 Takeda Revenue in Multi-Infarct Dementia Business (2015-2020)
13.7.5 Takeda Recent Development
13.8 Jubilant Cadista Pharmaceuticals
13.8.1 Jubilant Cadista Pharmaceuticals Company Details
13.8.2 Jubilant Cadista Pharmaceuticals Business Overview
13.8.3 Jubilant Cadista Pharmaceuticals Multi-Infarct Dementia Introduction
13.8.4 Jubilant Cadista Pharmaceuticals Revenue in Multi-Infarct Dementia Business (2015-2020)
13.8.5 Jubilant Cadista Pharmaceuticals Recent Development
13.9 Takeda Pharmaceutical
13.9.1 Takeda Pharmaceutical Company Details
13.9.2 Takeda Pharmaceutical Business Overview
13.9.3 Takeda Pharmaceutical Multi-Infarct Dementia Introduction
13.9.4 Takeda Pharmaceutical Revenue in Multi-Infarct Dementia Business (2015-2020)
13.9.5 Takeda Pharmaceutical Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Multi-Infarct Dementia Key Market Segments
Table 2. Key Players Covered: Ranking by Multi-Infarct Dementia Revenue
Table 3. Ranking of Global Top Multi-Infarct Dementia Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Multi-Infarct Dementia Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Pharmacological Treatment
Table 6. Key Players of Non Pharmacological Treatment
Table 7. Global Multi-Infarct Dementia Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Multi-Infarct Dementia Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Multi-Infarct Dementia Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Multi-Infarct Dementia Market Share by Regions (2015-2020)
Table 11. Global Multi-Infarct Dementia Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Multi-Infarct Dementia Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Multi-Infarct Dementia Market Growth Strategy
Table 17. Main Points Interviewed from Key Multi-Infarct Dementia Players
Table 18. Global Multi-Infarct Dementia Revenue by Players (2015-2020) (Million US$)
Table 19. Global Multi-Infarct Dementia Market Share by Players (2015-2020)
Table 20. Global Top Multi-Infarct Dementia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multi-Infarct Dementia as of 2019)
Table 21. Global Multi-Infarct Dementia by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Multi-Infarct Dementia Product Solution and Service
Table 24. Date of Enter into Multi-Infarct Dementia Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Multi-Infarct Dementia Market Size by Type (2015-2020) (Million US$)
Table 27. Global Multi-Infarct Dementia Market Size Share by Type (2015-2020)
Table 28. Global Multi-Infarct Dementia Revenue Market Share by Type (2021-2026)
Table 29. Global Multi-Infarct Dementia Market Size Share by Application (2015-2020)
Table 30. Global Multi-Infarct Dementia Market Size by Application (2015-2020) (Million US$)
Table 31. Global Multi-Infarct Dementia Market Size Share by Application (2021-2026)
Table 32. North America Key Players Multi-Infarct Dementia Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Multi-Infarct Dementia Market Share (2019-2020)
Table 34. North America Multi-Infarct Dementia Market Size by Type (2015-2020) (Million US$)
Table 35. North America Multi-Infarct Dementia Market Share by Type (2015-2020)
Table 36. North America Multi-Infarct Dementia Market Size by Application (2015-2020) (Million US$)
Table 37. North America Multi-Infarct Dementia Market Share by Application (2015-2020)
Table 38. Europe Key Players Multi-Infarct Dementia Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Multi-Infarct Dementia Market Share (2019-2020)
Table 40. Europe Multi-Infarct Dementia Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Multi-Infarct Dementia Market Share by Type (2015-2020)
Table 42. Europe Multi-Infarct Dementia Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Multi-Infarct Dementia Market Share by Application (2015-2020)
Table 44. China Key Players Multi-Infarct Dementia Revenue (2019-2020) (Million US$)
Table 45. China Key Players Multi-Infarct Dementia Market Share (2019-2020)
Table 46. China Multi-Infarct Dementia Market Size by Type (2015-2020) (Million US$)
Table 47. China Multi-Infarct Dementia Market Share by Type (2015-2020)
Table 48. China Multi-Infarct Dementia Market Size by Application (2015-2020) (Million US$)
Table 49. China Multi-Infarct Dementia Market Share by Application (2015-2020)
Table 50. Japan Key Players Multi-Infarct Dementia Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Multi-Infarct Dementia Market Share (2019-2020)
Table 52. Japan Multi-Infarct Dementia Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Multi-Infarct Dementia Market Share by Type (2015-2020)
Table 54. Japan Multi-Infarct Dementia Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Multi-Infarct Dementia Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Multi-Infarct Dementia Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Multi-Infarct Dementia Market Share (2019-2020)
Table 58. Southeast Asia Multi-Infarct Dementia Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Multi-Infarct Dementia Market Share by Type (2015-2020)
Table 60. Southeast Asia Multi-Infarct Dementia Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Multi-Infarct Dementia Market Share by Application (2015-2020)
Table 62. India Key Players Multi-Infarct Dementia Revenue (2019-2020) (Million US$)
Table 63. India Key Players Multi-Infarct Dementia Market Share (2019-2020)
Table 64. India Multi-Infarct Dementia Market Size by Type (2015-2020) (Million US$)
Table 65. India Multi-Infarct Dementia Market Share by Type (2015-2020)
Table 66. India Multi-Infarct Dementia Market Size by Application (2015-2020) (Million US$)
Table 67. India Multi-Infarct Dementia Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Multi-Infarct Dementia Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Multi-Infarct Dementia Market Share (2019-2020)
Table 70. Central & South America Multi-Infarct Dementia Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Multi-Infarct Dementia Market Share by Type (2015-2020)
Table 72. Central & South America Multi-Infarct Dementia Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Multi-Infarct Dementia Market Share by Application (2015-2020)
Table 74. Forest Laboratories Company Details
Table 75. Forest Laboratories Business Overview
Table 76. Forest Laboratories Product
Table 77. Forest Laboratories Revenue in Multi-Infarct Dementia Business (2015-2020) (Million US$)
Table 78. Forest Laboratories Recent Development
Table 79. Janssen Pharmaceuticals Company Details
Table 80. Janssen Pharmaceuticals Business Overview
Table 81. Janssen Pharmaceuticals Product
Table 82. Janssen Pharmaceuticals Revenue in Multi-Infarct Dementia Business (2015-2020) (Million US$)
Table 83. Janssen Pharmaceuticals Recent Development
Table 84. Novartis Pharmaceutical Company Details
Table 85. Novartis Pharmaceutical Business Overview
Table 86. Novartis Pharmaceutical Product
Table 87. Novartis Pharmaceutical Revenue in Multi-Infarct Dementia Business (2015-2020) (Million US$)
Table 88. Novartis Pharmaceutical Recent Development
Table 89. Pfizer Company Details
Table 90. Pfizer Business Overview
Table 91. Pfizer Product
Table 92. Pfizer Revenue in Multi-Infarct Dementia Business (2015-2020) (Million US$)
Table 93. Pfizer Recent Development
Table 94. Eisai Company Details
Table 95. Eisai Business Overview
Table 96. Eisai Product
Table 97. Eisai Revenue in Multi-Infarct Dementia Business (2015-2020) (Million US$)
Table 98. Eisai Recent Development
Table 99. Ortho-McNeil Pharmaceutical Company Details
Table 100. Ortho-McNeil Pharmaceutical Business Overview
Table 101. Ortho-McNeil Pharmaceutical Product
Table 102. Ortho-McNeil Pharmaceutical Revenue in Multi-Infarct Dementia Business (2015-2020) (Million US$)
Table 103. Ortho-McNeil Pharmaceutical Recent Development
Table 104. Takeda Company Details
Table 105. Takeda Business Overview
Table 106. Takeda Product
Table 107. Takeda Revenue in Multi-Infarct Dementia Business (2015-2020) (Million US$)
Table 108. Takeda Recent Development
Table 109. Jubilant Cadista Pharmaceuticals Business Overview
Table 110. Jubilant Cadista Pharmaceuticals Product
Table 111. Jubilant Cadista Pharmaceuticals Company Details
Table 112. Jubilant Cadista Pharmaceuticals Revenue in Multi-Infarct Dementia Business (2015-2020) (Million US$)
Table 113. Jubilant Cadista Pharmaceuticals Recent Development
Table 114. Takeda Pharmaceutical Company Details
Table 115. Takeda Pharmaceutical Business Overview
Table 116. Takeda Pharmaceutical Product
Table 117. Takeda Pharmaceutical Revenue in Multi-Infarct Dementia Business (2015-2020) (Million US$)
Table 118. Takeda Pharmaceutical Recent Development
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Multi-Infarct Dementia Market Share by Type: 2020 VS 2026
Figure 2. Pharmacological Treatment Features
Figure 3. Non Pharmacological Treatment Features
Figure 4. Global Multi-Infarct Dementia Market Share by Application: 2020 VS 2026
Figure 5. Academic Case Studies
Figure 6. Hospitals Case Studies
Figure 7. Other Case Studies
Figure 8. Multi-Infarct Dementia Report Years Considered
Figure 9. Global Multi-Infarct Dementia Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Multi-Infarct Dementia Market Share by Regions: 2020 VS 2026
Figure 11. Global Multi-Infarct Dementia Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Multi-Infarct Dementia Market Share by Players in 2019
Figure 14. Global Top Multi-Infarct Dementia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multi-Infarct Dementia as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Multi-Infarct Dementia Revenue in 2019
Figure 16. North America Multi-Infarct Dementia Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Multi-Infarct Dementia Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Multi-Infarct Dementia Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Multi-Infarct Dementia Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Multi-Infarct Dementia Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Multi-Infarct Dementia Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Multi-Infarct Dementia Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
認知症・運動障害治療の世界市場（～2026年） Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and personality change…- アルジマー病・認知症の世界市場（～2026年） The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and oth…
- マルチサービスビジネスゲートウェイ（MSBG）の世界市場（～2026年） A multi-service business gateway (MSBG) is a device that combines multiple network voice and data communications functions into a single device. Targeted at small and medium enterprises (SMEs), the MSBG integrates critical functions such as routing, VoIP, and security (virtual private networking, fi…
- マルチサービスビジネスゲートウェイの世界市場（～2026年） A multi-service business gateway is a device that integrates multiple network data and voice communication tasks into a single device. The multi-service business gateway solution combines crucial functions such as VoIP (voice over internet protocol), routing and security of firewall, virtual private…
- 多軸関節鏡検査の世界市場（～2026年） Arthroscopy (also called arthroscopic or keyhole surgery) is a minimally invasive surgical procedure on a joint in which an examination and sometimes treatment of damage is performed using an arthroscope, an endoscope that is inserted into the joint through a small incision. The increasing prevalenc…